Fibrosis and extracellular matrix deposition pathways in kidney tissue

Fibrosis and extracellular matrix (ECM) deposition pathways in kidney tissue represent the pathological process of excessive accumulation of fibrous connective tissue in the renal parenchyma. This process is a hallmark of chronic kidney disease (CKD) and leads to the progressive loss of renal function by replacing functional nephrons with non-functional scar tissue (PubMed: 30115754). The primary driver of this process is the activation of myofibroblasts, which are stimulated by pro-fibrotic cytokines like Transforming Growth Factor-beta 1 (TGF-beta1) (PubMed: 24103881). These pathways involve a complex interplay of cellular signaling, including the Smad protein family, and the dysregulation of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). Therapeutic strategies often focus on inhibiting these signaling cascades or blocking the renin-angiotensin-aldosterone system (RAAS) to slow the progression of fibrosis (PubMed: 11565080). Because this entry describes a broad biological process involving multiple molecular targets rather than a single protein, it is classified as a pathway rather than a discrete therapeutic target.

Other names

Renal fibrosisKidney fibrosisTubulointerstitial fibrosisGlomerulosclerosisExtracellular matrix remodeling

Modulation of pro-fibrotic signaling cascades, such as the TGF-beta/Smad pathway, and inhibition of myofibroblast activation to reduce the synthesis and deposition of collagen and other matrix proteins.